Back to results

Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection

Primary Purpose

Clostridium Difficile Infection

Status

Terminated

Phase

Phase 3

Locations

Canada

Study Type

Interventional

Intervention

Fidaxomicin

About this trial

This is an interventional treatment trial for Clostridium Difficile Infection focused on measuring recurrent, infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age 18 years or older.
Able to provide informed consent.
Willing and able to comply with all the required study procedures.
A positive stool test for C. difficile toxin/gene using either PCR or enzyme immunoassay within 3 months of recruitment.
History of at least ≥ 2 recurrent CDI within 6 months where recurrence is deﬁned as return of diarrhea consistent with CDI within 8 weeks following CDI symptom resolution for at least 24 hours after a minimum of 10-day course of standard antibiotic therapy and positive stool test for C. difficile toxin or toxin gene and/or ongoing symptoms consistent with CDI despite at least 5 days of treatment using oral vancomycin.
Has more than three unformed bowel movements or 200 mL of stool for individuals with a stool collection device such as rectal tube or colostomy during a 24-hour period at the time of initiation of fidaxomicin. Participants will be enrolled when they meet inclusion criteria 1 - 5; will be initiated at fidaxomicin when they have CDI symptoms and stool will be tested for C. difficile toxin/gene. Only those with positive stool for C. difficile toxin/gene with current episode of CDI will continue with the study
Females of child bearing potential must be willing to use acceptable birth control as per the Health Canada Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences.

Exclusion Criteria:

Planned or actively taking an investigational product for another study.
Prior fidaxomicin use.
Hypersensitivity to fidaxomicin or to any ingredient in the formulation or component of the container.
Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray or life expectancy of less than 72 hours.
Active gastroenteritis due to Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia or Campylobacter.
Anticipated requirement for systemic antibiotic therapy for more than 7 days during the study period.
Actively taking Saccharomyces boulardii or other probiotics other than yogurt.
Any condition that, in the opinion of the investigator, that the treatment may pose a health risk to the subject.
Pregnant or lactating.

Sites / Locations

Christine Lee

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fidaxomicin

Arm Description

30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.

Outcomes

Primary Outcome Measures

Clinical Response at 30-day Completion of Fidaxomicin

clinical response will be defined as those participants who have improvement in the number of bowel movements as determined by ≤ 3 unformed stools in a 24-hour period for 2 consecutive days during treatment and remaining well through study day 30.

Sustained Clinical Response 8 Weeks Following Completion of 30-day Course of Fidaxomicin

sustained clinical response will be defined as those participants who have improvement in the number of bowel movements as determined by ≤ 3 unformed stools in a 24-hour period for 2 consecutive days during treatment and remaining well 8 weeks following completion of fidaxomicin

Treatment Failure

patients not meeting the definition of cure and requiring additional antibiotics for current CDI episode

Secondary Outcome Measures

Full Information

NCT ID

NCT02395848

First Posted

February 26, 2015

Last Updated

June 13, 2022

Sponsor

McMaster University

1. Study Identification

Unique Protocol Identification Number

NCT02395848

Brief Title

Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection

Official Title

Prospective, Open-label Trial to Evaluate Efficacy of 30-day Duration of Fidaxomicin in Patients With Recurrent C. Difficile Infection

Study Type

Interventional

2. Study Status

Record Verification Date

June 2022

Overall Recruitment Status

Terminated

Why Stopped

Insufficient resource to complete the study

Study Start Date

July 2015 (undefined)

Primary Completion Date

August 30, 2021 (Actual)

Study Completion Date

August 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

McMaster University

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This is a medical research study designed to look at the safety and efficacy of 30-day course of fidaxomicin for treatment of recurrent CDI (Clostridium difficile Infection). CDI is an infection that results when the normal flora (resident bacteria) of the colon is substantially altered by antibiotic treatment. The decrease in this normal flora allows for the growth of the C. difficile bacteria. Fidaxomicin is an antibiotic which is approved by Health Canada for treatment of CDI. Only patients with a primary case of CDI or 1st episode of recurrent CDI have been studied using a 10-day course of fidaxomicin.

Detailed Description

Clostridium difficile (C. difficile) infection (CDI) is one of the most frequent causes of healthcare associated infections and its rates are also growing in the community. The efficacy of standard antibiotics especially for recurrent CDI is limited as oral vancomycin and metronidazole also suppress the growth of anaerobic bacteria such as Bacteroides fragilis group which protect against proliferation of C. difficile. In contrast, in vitro study has shown that fidaxomicin has negligible activity against B. fragilis. The persistent disruption of healthy colonic flora may be the reason for recurrences following a course of treatment with metronidazole or vancomycin. Fidaxomicin has shown to reduce recurrences by approximately 50% when compared to oral vancomycin for primary or 1st episode of recurrent CDI. Determining the efficacy and safety of 30-day duration of fidaxomicin for recurrent CDI through an open label clinical trial has important implications for policy making related to the drug reimbursement programs. In addition, the results of this study will be instrumental in demonstrating to the scientific and healthcare communities there may be a role for the 30-day course of fidaxomicin as a treatment modality for recurrent CDI. Curing CDI will restore the health and quality of life not just at the individual patient level but to the healthcare communities as well. Patients with refractory CDI require prolonged hospital admission, which increases the organism burden within the healthcare facilities. This in turn leads to the spread of the infection to other vulnerable patients. If a 30-day course of fidaxomicin proves to be safe and effective in curing patients with recurrent CDI, it will reduce the risk of severe complications in each patient and reduce transmission of CDI to other susceptible patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Clostridium Difficile Infection

Keywords

recurrent, infection

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

31 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Fidaxomicin

Arm Type

Experimental

Arm Description

30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.

Intervention Type

Drug

Intervention Name(s)

Fidaxomicin

Other Intervention Name(s)

Dificid

Intervention Description

200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI

Primary Outcome Measure Information:

Title

Clinical Response at 30-day Completion of Fidaxomicin

Description

Time Frame

30 days

Title

Sustained Clinical Response 8 Weeks Following Completion of 30-day Course of Fidaxomicin

Description

Time Frame

8 week following completion of fidaxomicin

Title

Treatment Failure

Description

patients not meeting the definition of cure and requiring additional antibiotics for current CDI episode

Time Frame

Up to 8 weeks following completion of fidaxomicin

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Age 18 years or older. Able to provide informed consent. Willing and able to comply with all the required study procedures. A positive stool test for C. difficile toxin/gene using either PCR or enzyme immunoassay within 3 months of recruitment. History of at least ≥ 2 recurrent CDI within 6 months where recurrence is deﬁned as return of diarrhea consistent with CDI within 8 weeks following CDI symptom resolution for at least 24 hours after a minimum of 10-day course of standard antibiotic therapy and positive stool test for C. difficile toxin or toxin gene and/or ongoing symptoms consistent with CDI despite at least 5 days of treatment using oral vancomycin. Has more than three unformed bowel movements or 200 mL of stool for individuals with a stool collection device such as rectal tube or colostomy during a 24-hour period at the time of initiation of fidaxomicin. Participants will be enrolled when they meet inclusion criteria 1 - 5; will be initiated at fidaxomicin when they have CDI symptoms and stool will be tested for C. difficile toxin/gene. Only those with positive stool for C. difficile toxin/gene with current episode of CDI will continue with the study Females of child bearing potential must be willing to use acceptable birth control as per the Health Canada Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences. Exclusion Criteria: Planned or actively taking an investigational product for another study. Prior fidaxomicin use. Hypersensitivity to fidaxomicin or to any ingredient in the formulation or component of the container. Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray or life expectancy of less than 72 hours. Active gastroenteritis due to Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia or Campylobacter. Anticipated requirement for systemic antibiotic therapy for more than 7 days during the study period. Actively taking Saccharomyces boulardii or other probiotics other than yogurt. Any condition that, in the opinion of the investigator, that the treatment may pose a health risk to the subject. Pregnant or lactating.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Christine H Lee, MD

Organizational Affiliation

Vancouver Island Health Authority

Official's Role

Principal Investigator

Facility Information:

Facility Name

Christine Lee

City

Victoria

State/Province

BC - British Columbia

ZIP/Postal Code

V8R 6CT

Country

Canada

12. IPD Sharing Statement

Learn more about this trial

Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection

We'll reach out to this number within 24 hrs